Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis

ArticleinCurrent opinion in ophthalmology 22(6):447-50 · September 2011
Impact Factor: 2.50 · DOI: 10.1097/ICU.0b013e32834be03b · Source: PubMed